Arecor Therapeutics plc
(“Arecor” or the “Company”)
ARECOR ANNOUNCES UPDATE ON INBRX-101
- Sanofi to acquire Inhibrx’s AATD therapy INBRX-101, which incorporates a novel formulation developed under a license agreement using Arecor’s Arestat™ technology, for up to $2.2 billion
- Terms of Arecor’s license agreement are unchanged. Arecor remains entitled to further payments on achievement of certain development, regulatory and commercial milestones along with annual Technology Access Fees post commercialisation